Discover
NVAX
Novavax, Inc.
8.04
5 x 8.04
16 x 8.05
bid
ask
-
0.04
0.46%
12:01 PM
timesize
| Ytd | 19.69% | |
| 1y | 11.40% |
8.02
day range
8.18
6.20
52 week range
11.97
| Open | 8.14 | Prev Close | 8.08 | Low | 8.02 | High | 8.18 | Mkt Cap | 1.33B |
| Vol | 707.59K | Avg Vol | 4.82M | EPS | 0.05 | P/E | 161.50 | Forward P/E | 2.58 |
| Beta | 2.43 | Short Ratio | 9.99 | Inst. Own | 69.46% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 9.28 | 200-d Avg | 8.53 | 1yr Est | 14.11 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-08-05 | 2026-06 | -0.4 | N/A | N/A | N/A |
| 2026-05-06 | 2026-03 | -0.25 | -0.06 | 0.19 | 76.00% |
| 2026-02-26 | 2025-12 | -0.66 | 0.11 | 0.77 | 116.67% |
| 2025-11-06 | 2025-09 | -1.08 | -0.62 | 0.46 | 42.59% |
| 2025-08-06 | 2025-06 | -0.07 | 0.62 | 0.69 | 985.71% |
| 2025-05-08 | 2025-03 | 0.71 | 2.93 | 2.22 | 312.68% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-06-11 | BTIG | Upgrade | Buy | Buy |
| 2026-05-06 | TD Cowen | Upgrade | Hold | Hold |
| 2026-02-27 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-01-20 | BTIG | Upgrade | Buy | Buy |
| 2025-11-18 | JP Morgan | Upgrade | Underweight | Underweight |
| 2025-11-10 | B. Riley Securities | Upgrade | Buy | Buy |
Profile
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-06-17 | ALTON GREGG H | Director | 47.69K | Conversion of Exercise of derivative security |
| 2026-03-02 | CASEY MARK J | Officer | 90.07K | Conversion of Exercise of derivative security |
| 2026-06-17 | DOUGLAS RICHARD H | Director | 73.22K | Conversion of Exercise of derivative security |
| 2026-03-02 | JACOBS JOHN C | Chief Executive Officer | 225.68K | Conversion of Exercise of derivative security |
| 2026-03-05 | KELLY JAMES PATRICK | Chief Financial Officer | 130.60K | Conversion of Exercise of derivative security |
| 2026-06-17 | MOTT DAVID M | Director | 79.77K | Conversion of Exercise of derivative security |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2025-12-30 | Vanguard Group Inc | 15.47M | 0.00 | 9.41% |
| 2026-03-30 | Shah Capital Management | 14.85M | 0.00 | 9.03% |
| 2026-03-30 | BlackRock Inc | 12.84M | 0.00 | 7.81% |
| 2026-03-30 | State Street Corp | 8.97M | 0.00 | 5.46% |
| 2026-03-30 | D. E. Shaw & Co LP | 7.71M | 0.00 | 4.69% |
| 2026-03-30 | Vanguard Portfolio Management, LLC | 7.15M | 0.00 | 4.35% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | State Street® SPDR® S&P® Biotech ETF | 7.50M | 0.00 | 4.56% |
| 2026-06-29 | Vanguard Total Stock Mkt Idx Inv | 5.20M | 0.00 | 3.16% |
| 2026-06-29 | iShares Russell 2000 ETF | 3.94M | 0.00 | 2.39% |
| 2026-06-29 | Vanguard Small Cap Index | 3.78M | 0.00 | 2.30% |
| 2026-06-29 | Vanguard Small Cap Growth Index Inv | 2.19M | 0.00 | 1.33% |
| 2026-06-29 | Vanguard Institutional Extnd Mkt Idx Tr | 1.89M | 0.00 | 1.15% |
Split
| Split | Date |
|---|---|
| 1 : 20 | 2019-05-10 |